血友病治療市場：製品タイプ、適応疾患、流通別-2025-2030年の世界予測

血友病治療市場は、2023年に143億2,000万米ドルと評価され、2024年には152億3,000万米ドルに達すると予測され、CAGR 6.45％で成長し、2030年には221億8,000万米ドルに達すると予測されています。

血友病治療には、血液凝固タンパク質の欠乏を特徴とする出血性疾患の管理を目的とした、因子補充療法、遺伝子療法、非因子療法を含む幅広い治療薬が含まれます。高度な血友病治療の必要性は、出血エピソードを減らし、身体的自立を改善し、関節損傷を最小限に抑えることによって患者のQOLを高める必要性から生じています。これらの治療は予防的治療とオンデマンド治療の両方に応用されており、予防的治療は重症の血友病患者における自然出血を予防するために行われています。主なエンドユーザーには病院、専門クリニック、在宅介護の現場などがあり、多様な治療管理の必要性を反映しています。同市場は、血友病管理に対する意識の高まり、政府の積極的な取り組み、医薬品の進歩、血友病の遺伝的有病率の増加といった要因によって支えられています。潜在的な治療法を約束する遺伝子治療の台頭や、長時間作用型の遺伝子組換え療法や非因子療法の開発には大きなビジネスチャンスがあります。ヘルスケアへのアクセスが増加している新興市場は、アンメット・メディカル・ニーズにより大きな成長機会を提供しています。しかし、治療費の高騰、厳しい規制の枠組み、阻害剤開発のリスクといった課題が大きな障害となっています。さらに、新興国市場の限られたヘルスケア・インフラが市場拡大を阻害する可能性もあります。生物工学、個別化医療、コスト効率の高い製造方法における革新は、事業の成長を促進する可能性があります。技術開発と市場浸透のための戦略的パートナーシップとともに、これらの分野への投資が望まれます。同市場は、継続的な研究と頻繁な製品発売による激しい競争が特徴です。企業は、治療の安全性と有効性を高め、アクセシビリティを向上させることに注力すべきです。市場の多様化と急速な進化に伴い、長期的な成功を確保するためには、リスクを軽減するための強固な市販後調査を維持し、患者教育を継続的に調整することが重要です。

市場力学：急速に進化する血友病治療市場の主要市場インサイトを公開

血友病治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 血友病患者数の増加
  • 血友病に関する診断および認知度の上昇
  • 遺伝子組換え血液凝固第VIII因子および血漿由来血液凝固第IX因子に対する需要の増加
• 市場抑制要因
  • 血漿由来製剤に関連する重篤な副作用
• 市場機会
  • 診断率の上昇と予防的治療の増加
  • 血友病治療における新たな進歩とイノベーション
• 市場の課題
  • 組み換え製品の高コストと厳しい政府規制

ポーターの5つの力：血友病治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、血友病治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血友病治療市場における外部からの影響の把握

外部マクロ環境要因は、血友病治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血友病治療市場における競合情勢の把握

血友病治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血友病治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血友病治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血友病治療市場における成功への道筋を描く

血友病治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 血友病患者の増加
    • 血友病に関する診断と認知度の高まり
    • 組み換えおよび血漿由来の第VIII因子および第IX因子の需要増加
  • 抑制要因
    • 血漿由来製品に関連する重篤な副作用
  • 機会
    • 診断率の向上と予防的治療の利用の増加
    • 血友病治療における新たな進歩と革新
  • 課題
    • 組み換え製品の高コストと厳しい政府規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血友病治療市場：製品タイプ別

• 抗線溶薬
• デスモプレシン
• 血漿由来凝固因子濃縮物
• 組換え凝固因子濃縮物

第7章 血友病治療市場：疾患適応症別

• 血友病A
• 血友病B
• ポリエチレン

第8章 血友病治療市場配布元

• eコマース
• 病院薬局
• 小売薬局

第9章 南北アメリカの血友病治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の血友病治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの血友病治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aptevo Therapeutics
• Biogen Inc.
• Biotest AG
• Bioverativ Inc.
• CSL Behring
• F. Hoffmann-La Roche AG
• Ferring B.V.
• Genentech, Inc.
• Grifols SA
• Kedrion S.P.A
• LAKEMEDEL AB
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. HEMOPHILIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. HEMOPHILIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEMOPHILIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 147. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Hemophilia Treatment Market was valued at USD 14.32 billion in 2023, expected to reach USD 15.23 billion in 2024, and is projected to grow at a CAGR of 6.45%, to USD 22.18 billion by 2030.

Hemophilia treatment encompasses a wide array of therapeutics, including factor replacement therapies, gene therapy, and non-factor therapies aimed at managing bleeding disorders characterized by a deficiency in blood-clotting proteins. The necessity for advanced hemophilia therapies stems from the need to elevate patients' quality of life by reducing bleeding episodes, improving physical independence, and minimizing joint damage. These treatments find applications in both prophylactic and on-demand settings, with prophylaxis being favored to prevent spontaneous bleeding in severe hemophilia cases. Key end-users include hospitals, specialty clinics, and home-care settings, reflecting the diverse treatment administration requirements. The market is propelled by factors such as heightened awareness about hemophilia management, favorable government initiatives, advancements in pharmaceutical products, and the growing genetic prevalence of the disorder. Prominent opportunities lie in the rise of gene therapy, which promises a potential cure and the development of long-acting recombinant and non-factor therapies. Emerging markets with increasing healthcare access offer substantial growth opportunities due to unmet medical needs. However, challenges like the high cost of therapies, stringent regulatory frameworks, and the risk of inhibitor development pose significant hindrances. Additionally, limited healthcare infrastructure in developing regions can impede market expansion. Innovation in bioengineering, personalized medicine, and cost-efficient manufacturing methods can fuel business growth. Investment in these areas, along with strategic partnerships for technology development and market penetration, is advisable. The hemophilia treatment market is characterized by intense competition with ongoing research and frequent product launches. Firms should focus on enhancing therapy safety and efficacy, and increasing accessibility. Maintaining robust post-market surveillance to mitigate risks and continuously tailoring patient education will be critical in ensuring long-term success as the market diversifies and evolves rapidly.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemophilia Treatment Market

The Hemophilia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of cases of hemophilia
  • Rising diagnostic and awareness related to Hemophilia
  • Increasing demand for recombinant and plasma-derived factor VIII and factor IX
• Market Restraints
  • Serious adverse effects associated with plasma-derived products
• Market Opportunities
  • Increased diagnosis rate and rise in the use of prophylactic treatment
  • Emerging advances and innovations in hemophilia treatment
• Market Challenges
  • High cost of recombinant products and stringent government regulations

Porter's Five Forces: A Strategic Tool for Navigating the Hemophilia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemophilia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemophilia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemophilia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemophilia Treatment Market

A detailed market share analysis in the Hemophilia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemophilia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemophilia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemophilia Treatment Market

A strategic analysis of the Hemophilia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemophilia Treatment Market, highlighting leading vendors and their innovative profiles. These include Aptevo Therapeutics, Biogen Inc., Biotest AG, Bioverativ Inc., CSL Behring, F. Hoffmann-La Roche AG, Ferring B.V., Genentech, Inc., Grifols SA, Kedrion S.P.A, LAKEMEDEL AB, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hemophilia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
• Based on Disease Indication, market is studied across Hemophilia A, Hemophilia B, and Polyethylene.
• Based on Distribution, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of cases of hemophilia
    • 5.1.1.2. Rising diagnostic and awareness related to Hemophilia
    • 5.1.1.3. Increasing demand for recombinant and plasma-derived factor VIII and factor IX
  • 5.1.2. Restraints
    • 5.1.2.1. Serious adverse effects associated with plasma-derived products
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased diagnosis rate and rise in the use of prophylactic treatment
    • 5.1.3.2. Emerging advances and innovations in hemophilia treatment
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of recombinant products and stringent government regulations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemophilia Treatment Market, by Product Type

• 6.1. Introduction
• 6.2. Antifibrinolytic Agents
• 6.3. Desmopressin
• 6.4. Plasma Derived Coagulation Factor Concentrates
• 6.5. Recombinant Coagulation Factor Concentrates

7. Hemophilia Treatment Market, by Disease Indication

• 7.1. Introduction
• 7.2. Hemophilia A
• 7.3. Hemophilia B
• 7.4. Polyethylene

8. Hemophilia Treatment Market, by Distribution

• 8.1. Introduction
• 8.2. E-commerce
• 8.3. Hospital Pharmacies
• 8.4. Retail Pharmacies

9. Americas Hemophilia Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hemophilia Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hemophilia Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aptevo Therapeutics
• 2. Biogen Inc.
• 3. Biotest AG
• 4. Bioverativ Inc.
• 5. CSL Behring
• 6. F. Hoffmann-La Roche AG
• 7. Ferring B.V.
• 8. Genentech, Inc.
• 9. Grifols SA
• 10. Kedrion S.P.A
• 11. LAKEMEDEL AB
• 12. Novo Nordisk A/S
• 13. Octapharma AG
• 14. Pfizer Inc.
• 15. Takeda Pharmaceutical Company Limited